First interim analysis of the German prospective, non-interventional study PaVe: first results on the clinical routine of ruxolitinib in polycythemia vera

被引：0
|
作者：
Griesshammer, M. [1 ]
von der Heyde, E. [2 ]
Weide, R. [3 ]
Reichert, D. [4 ]
Weniger, J. [5 ]
Schlag, R.
Hutzschenreuter, U. [6 ]
Becker, M. [7 ]
Just, M.
Hacker, E. [8 ]
Cavanna, D. [8 ]
Lengfelder, E. [9 ]
机构：
[1] Johannes Wesling Klinikum, Minden, Germany
[2] Gemeinschaftspraxis Dres Zander von der Heyde, Hannover, Germany
[3] Praxisklin Hamatol & Onkol, Koblenz, Germany
[4] Onkol Gemeinschaftspraxis Dres Reichert Janssen, Westerstede, Germany
[5] Gemeinschaftspraxis Hamatol & Onkol Dres Weniger, Erfurt, Germany
[6] Hamatol Onkol Gemeinschaftspraxis Dres Hutzschenr, Nordhorn, Germany
[7] Zentrum Hamatol & Onkol MVZ GmbH, Porta Westfalica, Germany
[8] Novartis Pharma GmbH, Nurnberg, Germany
[9] Univ Med Mannheim, Med Klin 3, Mannheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P544
引用
收藏
页码：148 / +
页数：2
相关论文
共 50 条
  • [41] Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany
    Brueckl, M.
    Laack, E.
    Reck, M.
    Griesinger, F.
    Schaefer, H.
    Kortsik, C.
    Gaska, T.
    Rawluk, J.
    Krueger, S.
    Kokowski, K.
    Budweiser, S.
    Schueler, A.
    Kiessling, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 524 - 524
  • [42] INTRAVENOUS AND ORAL TREOSULFAN IN THE ROUTINE TREATMENT OF OVARIAN CANCER: RESULTS OF A GERMAN NON-INTERVENTIONAL STUDY
    Chekerov, R.
    Ulmer, H. U.
    Reichert, D.
    Goehler, T.
    Klare, P.
    Sauer, U.
    Wischnik, A.
    Vehling-Kaiser, U.
    Becker, M.
    Hutzschenreuter, U.
    Ammon, A.
    Sehouli, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [43] Interim results from a prospective, non-interventional study on the use of rVIII-SingleChain in patients with haemophilia A
    Oldenburg, J.
    Juranek, S.
    Katsarou, O.
    El Fegoun, S. Benchikh
    Pabinger, I.
    HAEMOPHILIA, 2024, 30 : 50 - 51
  • [44] TOCILIZUMAB, DMARDS AND GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS - INTERIM ANALYSIS OF THE GERMAN NON-INTERVENTIONAL STUDY ICHIBAN
    Specker, C.
    Kaufmann, J.
    Vollmer, M. A.
    Kellner, H.
    Hoehle, M.
    Kuehne, C.
    Volberg, C.
    Henes, J. C.
    Zinke, S.
    Moosig, F.
    Bohl-Buehler, M.
    Sieburg, M.
    Aringer, M.
    Hofmann, M. W.
    Hellmann, P.
    Fliedner, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 494 - 495
  • [45] First subgroup interim analysis of German patients from a global non-interventional study in metastatic renal cell carcinoma patients treated with sorafenib - the PREDICT study
    Jaeger, D.
    Brehmer, B.
    Stauch, K.
    Yu, J.
    ONKOLOGIE, 2010, 33 : 106 - 106
  • [46] Influence of Tocilizumab on Employment and Use of SHI Services - Interim Analysis of a German non-interventional Study
    Specker, C.
    Fliedner, G.
    Kaufholz, C.
    Hofmann, M.
    Feist, E.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 106 - 107
  • [47] An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis
    te Boekhorst, Peter A. W.
    Theocharides, Alexandre
    Gisslinger, Heinz
    Devos, Timothy
    Lippert, Eric
    Sotiropoulos, Damianos
    Egyed, Miklos
    De Stefano, Valerio
    Accurso, Vincenzo
    Iurlo, Alessandra
    Dahm, Anders E. A.
    Garcia-Delgado, Regina
    Cantoni, Nathan
    Zuurman, Mike
    Zaiac, Michael
    Houtsma, Erik
    Iqbal, Amir
    Di Matteo, Paola
    Alvarez-Larran, Alberto
    BLOOD, 2020, 136
  • [48] Quality of life and efficacy of NEPA as CINV prophylaxis in highly or moderately emetogenic chemotherapy - interim results of a German prospective non-interventional study
    Karthaus, M.
    Schilling, J.
    Rauh, J.
    Heilmann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 184 - 184
  • [49] Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin.
    Schmidt, Marcus
    Kummel, Sherko
    Ruf-Doerdelmann, Antonia
    Distelrath, Andrea
    Wacker, Juergen
    Schmatloch, Sabine
    Keitel, Stella
    Luedtke-Heckenkamp, Kerstin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice
    Luedtke-Heckenkamp, K.
    Kuemmel, S.
    Ruf-Doerdelmann, A.
    Distelrath, A.
    Wacker, J.
    Schmatloch, S.
    Busch-Liles, S.
    Schmidt, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345